Journal of Hepatology
Volume 44, Issue 1 , Pages 62-67 , January 2006

Safety and efficacy of adefovir dipivoxil in patients infected with lamivudine-resistant hepatitis B and HIV-1

  • Yves Benhamou

      Affiliations

    • Groupe Hospitalier Pitie-Salpetriere, Service de d'Hépato-Gastroentérologie, Paris, France
    • Corresponding Author InformationCorresponding author.
    • ,
  • Vincent Thibault

      Affiliations

    • Groupe Hospitalier Pitie-Salpetriere, Laboratoire Institutions:de Virologie, Paris, France
    • ,
  • Pamela Vig

      Affiliations

    • Gilead Sciences, Foster City, Foster City, California, CA, USA
    • ,
  • Vincent Calvez

      Affiliations

    • Groupe Hospitalier Pitie-Salpetriere, Laboratoire Institutions:de Virologie, Paris, France
    • ,
  • Anne-Genevieve Marcelin

      Affiliations

    • Groupe Hospitalier Pitie-Salpetriere, Laboratoire Institutions:de Virologie, Paris, France
    • ,
  • Marie-Hélène Fievet

      Affiliations

    • Groupe Hospitalier Pitie-Salpetriere, Service de Pharmacie, Paris, France
    • ,
  • Graeme Currie

      Affiliations

    • Gilead Sciences, Foster City, Foster City, California, CA, USA
    • ,
  • Chuy G. Chang

      Affiliations

    • Gilead Sciences, Foster City, Foster City, California, CA, USA
    • ,
  • Lu Biao

      Affiliations

    • Gilead Sciences, Foster City, Foster City, California, CA, USA
    • ,
  • Shelly Xiong

      Affiliations

    • Gilead Sciences, Foster City, Foster City, California, CA, USA
    • ,
  • Carol Brosgart

      Affiliations

    • Gilead Sciences, Foster City, Foster City, California, CA, USA
    • ,
  • Thierry Poynard

      Affiliations

    • Groupe Hospitalier Pitie-Salpetriere, Service de d'Hépato-Gastroentérologie, Paris, France

Received 16 March 2005 ,Revised 21 July 2005 ,Accepted 5 August 2005.

References 

  1. Maddrey WC. Hepatitis B: an important public health issue. J Med Virol. 2000;61:362–366
  2. Yu M-W, Hsu F-C, Sheen I-S, Chu C-M, Lin D-Y, Chen C-J, et al. Prospective study of hepatocellular carcinoma and liver cirrhosis in asymptomatic chronic hepatitis B virus carriers. Am J Epidemiol. 1997;145:1039–1047
  3. Vallet-Pichard A, Pol Stanislas . Hepatitis viruses and human immunodeficieny virus co-infection: pathogenesis and treatment. J Hepatol. 2004;41:156–166
  4. Bodsworth NJ, Cooper DA, Donovan B. The influence of human immunodeficiency virus type 1 infection on the development of the hepatitis B virus carrier state. J Infect Dis. 1991;163:1138–1140
  5. Gilson RJ, Hawkins AE, Beecham MR, Ross E, Waite J, Briggs M, et al. Interactions between HIV and hepatitis B virus in homosexual men: effects on the natural history of infection. AIDS. 1997;11:597–606
  6. Thio CL, Seaberg EC, Skolasky R, Phair J, Visscher B, Munoz A, et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the multicenter cohort study (MACS). Lancet. 2002;360:1921–1926
  7. Lai C-L, Chien R-N, Leung NWY, Chang T-T, Guan R, Tai D-I, et al. A one-year trial of lamivudine for chronic hepatitis B. N Engl J Med. 1998;339:61–68
  8. Bartholomew MM, Jansen RW, Jeffers LJ, Reddy KR, Johnson LC, Buzendahl H, et al. Hepatitis B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation. Lancet. 1997;349:20–22
  9. Benhamou Y, Bochet M, Thibault V, Di Martino V, Caumes E, Bricaire F, et al. Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients. Hepatology. 1999;30:1302–1306
  10. Thibault V, Benhamou Y, Seguret C, Bochet M, Katlama C, Bricaire F, et al. Hepatitis B virus (HBV) mutations associated with resistance to lamivudine in patients coinfected with HBV and human immunodeficiency virus. J Clin Microbiol. 1999;37:3013–3016
  11. Lai C-L, Dienstag J, Schiff E, Leung NWY, Atkins M, Hunt C, et al. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis. 2003;36:687–696
  12. Dienstag JL, Perrillo RP, Schiff ER, Bartholomew M, Vicary C, Rubin M. A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med. 1995;333:1657–1661
  13. Benhamou Y, Katlama C, Lunel F, Coutellier A, Dohin E, Hamm N, et al. Effects of lamivudine on replication of hepatitis B virus in HIV-infected men. Ann Inter Med. 1996;125:705–712
  14. Atkins M, Hunt CM, Brown N, Gray F, Sanathanan L, Woessner M, et al. Clinical significance of YMDD mutant hepatitis B virus (HBV) in a large cohort of lamivudine-treated hepatitis B patients [abstract]. Hepatology. 1998;28:319A;[Abstract 625]
  15. Chang TT, Lai CL, Liaw YF, Guan R, Lim SG, Lee CM, et al. Incremental increases in HBeAg seroconversion and continued ALT normalization in Asian chronic HBV (CHB) patients treated with lamivudine for four years. Antivir Ther. 2000;5:44
  16. Perrillo RP. Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease. Gastroenterology. 2001;120:1009–1022
  17. Bruno R, Sacchi P, Malfitano A, Filice G. YMDD-mutant HBV strain as a cause of liver failure in an HIV-infected patient. Gastroenterology. 2001;121:1027–1028
  18. Bonacini M. Fulminant hepatitis B due to a lamivudine-resistant mutant of HBV in a patient coinfected with HIV. Gastroenterology. 2002;122:244–245
  19. Marcellin P, Chang T-T, Lim SG, Tong MJ, Sievert W, Shiffman ML, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med. 2003;348:808–816
  20. Hadziyannis SJ, Tassopoulos N, Heathcote EJ, Chang T-T, Kitis G, Rizzetto M, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med. 2003;348:800–807
  21. Benhamou Y, Bochet M, Thibault V, Calvez V, Fievet MH, Vig P, et al. Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study. Lancet. 2001;358:718–723
  22. METAVIR Cooperative Study Group . Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology. 1994;20:15–20
  23. Benhamou Y, Bochet M, Thibault V, Calvez V, Fievet MH, Sullivan M, et al. Safety and efficacy of long-term adefovir dipivoxil (ADV) for lamivudine-resistant (LAM-R) HBV in HIV infected patients [abstract]. J Hepatol. 2002;36:138;[Abstract 496]
  24. Angus P, Vaughan R, Xiong S, Yang H, Delaney W, Gibbs C, et al. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology. 2003;125:292–297
  25. Qi X, Snow A, Thibault V, Zhu Y, Curtis M, Hadziyannis S, et al. Long-term incidence of adefovir dipivoxil (ADV) resistance in chronic hepatitis B (CHB) patients after 144 weeks of therapy [abstract]. J Hepatol. 2004;40:20–21[Abstract 57]

☆ The authors who have taken part in this study have declared a relationship with the manufacturers of the drugs involved and they received funding from the drug companies involved to carry out their research.

PII: S0168-8278(05)00603-3

doi: 10.1016/j.jhep.2005.08.020

Journal of Hepatology
Volume 44, Issue 1 , Pages 62-67 , January 2006

Article Tools

* Image Usage & Resolution